Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Aquestive Therapeutics, Inc. AQST

Healthcare  —  Drug Manufacturers Specialty & Generic
4.68 (0.14) (2.90%) as of 25 Sep
Market cap
$605.0M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Aquestive Therapeutics, Inc. (AQST) Business Profile

Updated before January 2025

Company Overview

Aquestive Therapeutics, Inc. (AQST) is a specialty pharmaceutical company that focuses on developing and commercializing innovative products to address unmet medical needs. Founded in 2004 and headquartered in Warren, New Jersey, the company has established itself as a leader in the development of orally administered therapies. Aquestive leverages its proprietary PharmFilm® technology to create unique drug delivery solutions that improve patient outcomes and convenience. The company is led by a team of experienced executives, including Daniel Barber, who serves as the Chief Executive Officer, and John Maxwell, the Chief Financial Officer. Their leadership has been instrumental in driving the company’s growth and innovation.

Core Business Segments

Aquestive Therapeutics operates primarily in the pharmaceutical sector, with a focus on the following core business segments:

1. Orally Administered Therapeutics

Aquestive’s flagship products are based on its proprietary PharmFilm® technology, which enables the delivery of drugs through thin, dissolvable films. This technology is designed to enhance the efficacy, safety, and convenience of medications. Key products in this segment include:

  • Sympazan®: An oral film formulation of clobazam, used for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS).
  • Exservan™: An oral film formulation of riluzole, used for the treatment of amyotrophic lateral sclerosis (ALS).

2. Licensing and Co-Development

Aquestive collaborates with other pharmaceutical companies to develop and commercialize products using its PharmFilm® technology. This segment generates revenue through licensing agreements, milestone payments, and royalties.

3. Pipeline Development

Aquestive has a robust pipeline of products in various stages of development. These include treatments for central nervous system (CNS) disorders, epilepsy, and other therapeutic areas. Notable pipeline candidates include:

  • AQST-109: A sublingual film formulation of epinephrine for the treatment of anaphylaxis.
  • AQST-108: A sublingual film formulation of epinephrine for the treatment of severe allergic reactions.

Business Model

Aquestive Therapeutics operates on a hybrid business model that combines proprietary product development with strategic partnerships. The company generates revenue through:

  • Product Sales: Direct sales of its proprietary products, such as Sympazan® and Exservan™.
  • Licensing Agreements: Partnering with other pharmaceutical companies to develop and commercialize products using its PharmFilm® technology.
  • Royalties and Milestone Payments: Earning royalties and milestone payments from licensing agreements and co-development projects.

Aquestive’s business model is designed to maximize the value of its proprietary technology while diversifying its revenue streams.

Strategic Direction

Aquestive Therapeutics is focused on achieving long-term growth through innovation and strategic partnerships. Key elements of its strategic direction include:

  • Expanding the Product Portfolio: Aquestive is actively developing new products to address unmet medical needs, particularly in the CNS and allergy treatment markets.
  • Global Expansion: The company aims to expand its presence in international markets through strategic partnerships and licensing agreements.
  • Sustainability Goals: Aquestive is committed to minimizing its environmental impact by adopting sustainable manufacturing practices and reducing waste.
  • Advancing Pipeline Candidates: The company is prioritizing the development and commercialization of its pipeline candidates, such as AQST-109 and AQST-108.

Competitive Landscape

Aquestive Therapeutics operates in a highly competitive pharmaceutical market. Key competitors include:

  • Eli Lilly and Company: A global leader in the development of CNS therapies.
  • Pfizer Inc.: A major player in the pharmaceutical industry with a diverse product portfolio.
  • Teva Pharmaceutical Industries: Known for its expertise in generic and specialty medicines.
  • BioDelivery Sciences International, Inc.: A competitor specializing in drug delivery technologies similar to Aquestive’s PharmFilm®.

Aquestive differentiates itself through its proprietary technology and focus on patient-centric solutions.

Risk Factors

Aquestive Therapeutics faces several risks that could impact its business operations and financial performance:

  • Market Dependence: The company relies heavily on the success of its proprietary products and pipeline candidates.
  • Regulatory Challenges: The pharmaceutical industry is subject to stringent regulatory requirements, which could delay product approvals.
  • Supply Chain Disruptions: Any disruptions in the supply chain could affect the production and distribution of its products.
  • Competition: Intense competition from larger pharmaceutical companies could limit Aquestive’s market share.
  • Financial Risks: As a smaller company, Aquestive may face challenges in securing funding for its research and development activities.

Recent Developments

Aquestive Therapeutics has made significant progress in recent years, including:

  • Advancement of AQST-109: The company has reported positive clinical trial results for AQST-109, its sublingual film formulation of epinephrine.
  • Partnerships and Licensing Agreements: Aquestive has entered into new licensing agreements to expand the reach of its PharmFilm® technology.
  • Regulatory Approvals: The company has received regulatory approvals for its products in key markets, enabling it to expand its customer base.
  • COVID-19 Impact: Despite challenges posed by the COVID-19 pandemic, Aquestive has maintained its focus on innovation and growth.

Investment Considerations

Investors considering Aquestive Therapeutics should weigh the following strengths and risks:

Strengths

  • Innovative Technology: Proprietary PharmFilm® technology provides a competitive edge.
  • Robust Pipeline: A strong pipeline of products targeting high-growth therapeutic areas.
  • Strategic Partnerships: Collaborations with leading pharmaceutical companies enhance revenue potential.

Risks

  • Regulatory Uncertainty: Delays in product approvals could impact revenue.
  • Market Competition: Intense competition from larger players in the pharmaceutical industry.
  • Financial Constraints: Limited financial resources may hinder growth and development.

Conclusion

Aquestive Therapeutics, Inc. is a dynamic pharmaceutical company with a strong focus on innovation and patient-centric solutions. Its proprietary PharmFilm® technology and robust pipeline position it as a leader in the development of orally administered therapies. While the company faces challenges such as regulatory hurdles and market competition, its strategic direction and commitment to growth make it a compelling player in the pharmaceutical industry. With a focus on expanding its product portfolio and entering new markets, Aquestive is well-positioned for future growth and success.